Compare Torrent Pharma with Sanofi India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs SANOFI INDIA - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA SANOFI INDIA TORRENT PHARMA/
SANOFI INDIA
 
P/E (TTM) x 34.4 42.1 81.6% View Chart
P/BV x 8.7 8.6 101.4% View Chart
Dividend Yield % 0.7 1.0 68.9%  

Financials

 TORRENT PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-19
SANOFI INDIA
Dec-18
TORRENT PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1,9646,840 28.7%   
Low Rs1,2454,630 26.9%   
Sales per share (Unadj.) Rs453.41,203.1 37.7%  
Earnings per share (Unadj.) Rs25.8165.3 15.6%  
Cash flow per share (Unadj.) Rs62.3209.9 29.7%  
Dividends per share (Unadj.) Rs17.0084.00 20.2%  
Dividend yield (eoy) %1.11.5 72.3%  
Book value per share (Unadj.) Rs279.2963.6 29.0%  
Shares outstanding (eoy) m169.2223.03 734.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.54.8 74.2%   
Avg P/E ratio x62.234.7 179.3%  
P/CF ratio (eoy) x25.827.3 94.3%  
Price / Book Value ratio x5.76.0 96.6%  
Dividend payout %65.950.8 129.7%   
Avg Mkt Cap Rs m271,513132,078 205.6%   
No. of employees `00013.63.3 411.9%   
Total wages/salary Rs m14,0384,068 345.1%   
Avg. sales/employee Rs Th5,642.68,393.8 67.2%   
Avg. wages/employee Rs Th1,032.41,232.4 83.8%   
Avg. net profit/employee Rs Th320.91,153.0 27.8%   
INCOME DATA
Net Sales Rs m76,72827,708 276.9%  
Other income Rs m571897 63.6%   
Total revenues Rs m77,29928,605 270.2%   
Gross profit Rs m19,8316,235 318.1%  
Depreciation Rs m6,1771,027 601.5%   
Interest Rs m5,0387 71,964.3%   
Profit before tax Rs m9,1876,098 150.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,5700-   
Tax Rs m1,2542,292 54.7%   
Profit after tax Rs m4,3633,806 114.6%  
Gross profit margin %25.822.5 114.9%  
Effective tax rate %13.637.6 36.3%   
Net profit margin %5.713.7 41.4%  
BALANCE SHEET DATA
Current assets Rs m50,37515,922 316.4%   
Current liabilities Rs m51,6536,235 828.4%   
Net working cap to sales %-1.735.0 -4.8%  
Current ratio x1.02.6 38.2%  
Inventory Days Days9264 144.7%  
Debtors Days Days6821 327.3%  
Net fixed assets Rs m83,6487,539 1,109.5%   
Share capital Rs m846230 367.9%   
"Free" reserves Rs m46,39721,962 211.3%   
Net worth Rs m47,24422,192 212.9%   
Long term debt Rs m39,1290-   
Total assets Rs m141,20929,839 473.2%  
Interest coverage x2.8872.1 0.3%   
Debt to equity ratio x0.80-  
Sales to assets ratio x0.50.9 58.5%   
Return on assets %6.712.8 52.1%  
Return on equity %9.217.2 53.8%  
Return on capital %12.327.5 44.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m22,1037,587 291.3%   
Fx outflow Rs m5,5227,145 77.3%   
Net fx Rs m16,581442 3,751.4%   
CASH FLOW
From Operations Rs m17,9813,739 480.9%  
From Investments Rs m-2,413-731 330.1%  
From Financial Activity Rs m-13,145-1,972 666.6%  
Net Cashflow Rs m2,3801,036 229.7%  

Share Holding

Indian Promoters % 71.5 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 7.0 14.4 48.8%  
FIIs % 12.6 14.6 86.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 10.5 83.8%  
Shareholders   26,511 15,184 174.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   ELDER PHARMA  FDC  SUN PHARMA  STRIDES PHARMA SCIENCE  TTK HEALTHCARE  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Bloodbath on Dalal Street: 6 Reasons Why Sensex Nosedived 1,939 Points Today(Closing)

Indian share markets witnessed a sharp sell-off today and ended deep in the red.

Related Views on News

SANOFI INDIA Announces Quarterly Results (2QFY21); Net Profit Up 5.0% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 5.0% YoY). Sales on the other hand came in at Rs 7 bn (down 11.9% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)

Oct 27, 2020 | Updated on Oct 27, 2020

For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY21); Net Profit Up 39.9% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 39.9% YoY). Sales on the other hand came in at Rs 7 bn (down 5.0% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY20); Net Profit Down 8.1% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, SANOFI INDIA has posted a net profit of Rs 854 m (down 8.1% YoY). Sales on the other hand came in at Rs 8 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Intraday Trading for a Living(Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Feb 26, 2021 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS